Back to Directory

Iris Mustich

Email

imustich@fhi360.org

Phone

919-627-6432

Institution

FHI 360

Title

Clinical Research Manager

Address

FHI 360
359 Blackwell St
Ste 200
Durham, NC 27701
United States of America

Request an Update

Affiliated Studies

IMPAACT 2051: Phase II Study of the Pharmacokinetics, Safety, Tolerability, and Anti-Mycobacterial Activity of Pretomanid with Bedaquiline and Linezolid, with or without Moxifloxacin, in Children with Rifampicin-Resistant Tuberculosis

DAIDS Number

39258

Research Area

Tuberculosis

Study Status

In Development

IMPAACT 2036: Phase I/II Study of the Safety, Tolerability, Acceptability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living with HIV-1, Two to Less Than 12 Years of Age

DAIDS Number

38932

Research Area

Therapeutics

Study Status

Enrolling

IMPAACT 2020: Phase II Study of Shortened Oral Treatment for Rifampicin-Resistant Tuberculosis in Children

DAIDS Number

38505

Research Area

Tuberculosis

Study Status

Withdrawn

IMPAACT 2034: Phase 1 Study of the Pharmacokinetics, Safety, and Acceptability of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children with Rifampicin-Resistant Tuberculosis

DAIDS Number

38754

Research Area

Tuberculosis

Study Status

Participants Off Study and Primary Analysis Completed

IMPAACT 2019: Phase I/II Study of the Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less than 12 Years of Age

DAIDS Number

38504

Research Area

Therapeutics

Study Status

Participants Off Study and Primary Analysis Completed

Show All